- Home
- LWAY vs MNPR Comparison
LWAY vs MNPR Comparison
Compare LWAY & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LWAY | MNPR |
|---|---|---|
| Founded | 1986 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 410.6M | 368.9M |
| IPO Year | 1995 | 2019 |
Fundamental Metrics
Financial Performance| Metric | LWAY | MNPR |
|---|---|---|
| Price | $24.18 | $58.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | $34.50 | ★ $107.00 |
| AVG Volume (30 Days) | 84.6K | ★ 160.0K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 48.33 | ★ 54.99 |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $103,350,000.00 | N/A |
| Revenue This Year | $16.64 | N/A |
| Revenue Next Year | $17.28 | N/A |
| P/E Ratio | $86.67 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.31 | $28.40 |
| 52 Week High | $34.20 | $105.00 |
Technical Indicators
Market Signals| Indicator | LWAY | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 43.35 | 52.54 |
| Support Level | $23.01 | $50.60 |
| Resistance Level | $25.37 | $61.51 |
| Average True Range (ATR) | 1.15 | 4.38 |
| MACD | -0.39 | 0.47 |
| Stochastic Oscillator | 20.15 | 51.18 |
Price Performance
Historical ComparisonAbout LWAY Lifeway Foods Inc.
Lifeway Foods Inc is engaged in manufacturing probiotic, cultured, functional dairy health food products. Its primary product is drinkable kefir, which is a cultured dairy product. Its product categories are Drinkable Kefir, which is the key revenue-driving product, European-style soft cheeses, Cream, ProBugs, Frozen Kefir, and Other dairy. The company manufactures and markets products under the Lifeway and Fresh Made brand names, as well as under private labels on behalf of customers. It sells the products through a direct sales force, brokers, and distributors.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.